Research programme: therapeutic monoclonal antibodies - Bayer HealthCare/BioInvent International
Latest Information Update: 04 Nov 2017
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; BioInvent International
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Sweden (Parenteral)
- 14 Oct 2013 Early research is ongoing in Sweden
- 12 Mar 2008 Early research in Undefined indication in Sweden (Parenteral)